Mutational Landscape of Patients Treated With TG4050, an Individualized Neoantigen Therapeutic Vaccine In Early-Stage Cancer Treatment

• Phase 1 study of a viral-vectored individualized neoantigen vaccine in HNSCC
• Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
• Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach

Speakers:

Alessandro Riva

Chairman & Chief Executive Officer

Transgene